Mereo Biopharma Group Plc ADR [NASDAQ: MREO] stock went on an upward path that rose over 3.89% on Wednesday, amounting to a one-week price increase of more than 6.52%.
Over the last 12 months, MREO stock dropped by -16.00%. The one-year Mereo Biopharma Group Plc ADR stock forecast points to a potential upside of 60.48. The average equity rating for MREO stock is currently 1.11, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $467.46 million, with 159.00 million shares outstanding and 132.68 million shares in the current float. Compared to the average trading volume of 1.37M shares, MREO stock reached a trading volume of 4987038 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Mereo Biopharma Group Plc ADR [MREO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MREO shares is $7.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MREO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Mereo Biopharma Group Plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 27, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on December 06, 2024, representing the official price target for Mereo Biopharma Group Plc ADR stock. Previously, the target price had yet another raise to $8, while Robert W. Baird analysts kept a Outperform rating on MREO stock.
The Price to Book ratio for the last quarter was 7.78, with the Price to Cash per share for the same quarter was set at 0.39.
MREO Stock Performance Analysis:
Mereo Biopharma Group Plc ADR [MREO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.52. With this latest performance, MREO shares gained by 7.30% in over the last four-week period, additionally sinking by -21.18% over the last 6 months – not to mention a drop of -16.00% in the past year of trading.
Insight into Mereo Biopharma Group Plc ADR Fundamentals:
Return on Equity for this stock declined to -76.20%, with Return on Assets sitting at -76.20%.
MREO Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MREO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mereo Biopharma Group Plc ADR go to 25.31%.
Mereo Biopharma Group Plc ADR [MREO] Institutonal Ownership Details
There are presently around $76.57%, or 77.31% of MREO stock, in the hands of institutional investors. The top three institutional holders of MREO stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 15.31 million shares, which is approximately 2.1506%. ADAGE CAPITAL PARTNERS GP, L.L.C., holding 11.79 million shares of the stock with an approximate value of $$42.45 million in MREO stocks shares; and ADAGE CAPITAL PARTNERS GP, L.L.C., currently with $$33.42 million in MREO stock with ownership which is approximately 1.3043%.
